Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

First FDA-Approved Recombinant von Willebrand Factor, Vonvendi, Now Available for von Willebrand Disease

The following is excerpted from a press release from Baxalta, now a part of Shire. Read the press release in it’s entirety here. Shire has announced that Vonvendi [von Willebrand factor (Recombinant)], indicated for the on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease, is now […]

Industry News

Biogen Names New Spin Off, Bioverativ; Aiming for Early 2017 Launch

The following is an excerpt from FierceBiotech.com To read the article in full, click here. Biogen previously announced its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new company will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq […]

Industry News

Shire Discontinues Hemophilia Gene Therapy Drug Development

The following is an excerpt from xconomy.com. To read the article in full, click here. On a conference call Tuesday, Shire CEO Flemming Ornskov said that the Dublin and Lexington, MA, company has discontinued development of BAX 335, an experimental gene therapy for hemophilia B. Prior to the merger of Baxalta and Shire, Baxalta had indicated plans […]

Industry News

Genentech Presents Latest Data on Emicizumab (ACE910)

Note: The below is an edited version of an article originally published on BusinessWire.  The original article can be read in their entirety here. The latest data from an ongoing Japanese Phase I/II study of Emicizumab were presented earlier this week at the World Federation of Hemophilia 2016 World Congress.  Emicizumab (a product being developed by […]

Industry News

BioMarin Releases Results of Phase 1/2 Study of Gene Therapy Treatment

Note: The below is an edited version of a press release issued by BioMarin Pharmaceutical Inc. The original release can be read in its entirety here. BioMarin Pharmaceutical announced today positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. Nine patients with severe hemophilia […]

Industry News

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in its entirety here. Sangamo BioSciences, Inc. announced the presentation of preclinical data that supports the clinical development of its new proprietary gene therapy for the treatment of hemophilia A. This new therapeutic comprises an adeno-associated […]

Industry News

uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B

Note: The below is an edited version of an article originally published on Globe Newswire. The original release can be read in its entirety here. uniQure N.V. yesterday announced updated clinical data from its ongoing Phase I/II trial of AMT-060, its proprietary, investigational gene therapy, in patients with severe hemophilia B.  The updated data show that […]

Industry News

CSL Behring Presents Phase 3 Data about Afstyla for Hemophilia A

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here. CSL Behring today presented data from a Phase III pivotal study of Afstyla [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress […]

medical_news_600x600

Voluntary Withdrawals of Helixate FS & Kogenate FS

As part of HFA’s ongoing mission to assist and advocate for the bleeding disorders community, this medical news is being issued to keep you informed about product safety. About These Withdrawals CSL Behring is initiating a voluntarily recall of two lots of its hemophilia A drug Helixate FS containing active ingredient manufactured before November 2015. […]

Industry News

Adynovate Phase 3 Efficacy and Safety Data in Children to be Presented

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here. _________________________________________________________________________________________ Shire will present additional data on the clinical experience of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant Factor VIII (rFVIII) replacement for hemophilia A, during the International […]

Page 5 of 2412345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community